Lifestyle modification remains the primary intervention for fatty liver disease and its subtype, metabolic dysfunction-associated steatohepatitis (MASH). Pharmacological therapies for MASH are still inconclusive, with resmetirom currently the only FDA-approved drug. Given the strong between MASH, obesity, and type 2 diabetes, an ongoing clinical trial has evaluated the effectiveness of semaglutide in 1,197 patients with MASH and fibrosis. The study found that semaglutide significantly resolved steatohepatitis without worsening fibrosis in 62.9% of patients compared to 34.3% in the placebo group.
It also reduced fibrosis without worsening steatohepatitis in 36.8% of patients versus 22.4% with placebo. Furthermore, semaglutide simultaneously resolved steatohepatitis and reduced liver fibrosis in 32.7% of patients, compared to 16.1% in the placebo group. These findings suggest that…
